Cite
HARVARD Citation
Duveau, N. et al. (2017). Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab. Digestive and liver disease. 49 (2), pp. 163-169. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Duveau, N. et al. (2017). Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab. Digestive and liver disease. 49 (2), pp. 163-169. [Online].